Desvenlafaxine Tablet, Extended Release
Product Images NDC 10135-821

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 10135-821). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Marlex Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

821-10 (821 10)

Desvenlafaxine 50 mg extended-release tablets label from Marlex Pharmaceuticals, Inc. The label states the tablet strength as 50 mg in a 1000-tablet package. It includes instructions to swallow whole and keep out of reach of children, along with storage conditions. The label specifies the product as prescription only and provides the NDC number.*

FDA Label Image

0821-14 (821 14)

Desvenlafaxine Extended Release Tablets 50 mg packaging label from Marlex Pharmaceuticals, Inc. The label states each tablet contains 76 mg desvenlafaxine succinate equivalent to 50 mg desvenlafaxine, intended for oral use. It provides storage instructions at 20° to 25°C (68° to 77°F) with allowed excursions and advises swallowing whole without breaking or chewing. It includes a barcode and NDC number 10135-0821-14.*

FDA Label Image

821-30 (821 30)

Desvenlafaxine Extended-Release Tablets 50 mg oral tablets in a 30-count package from Marlex Pharmaceuticals, Inc. The label includes dosage storage instructions and a barcode with NDC 10135-0821-30.*

FDA Label Image

821-90 (821 90)

Desvenlafaxine Extended-Release Tablets 50 mg label from Marlex Pharmaceuticals, Inc. The label states each tablet contains 76 mg desvenlafaxine succinate equivalent to 50 mg desvenlafaxine. It includes storage instructions, dosage form, quantity (90 tablets), and distributor information.*

FDA Label Image

822-10 (822 10)

Label for Desvenlafaxine extended-release tablets, 100 mg strength, oral dosage form. The label states the product contains 1000 tablets and is manufactured by Marlex Pharmaceuticals, Inc. It includes instructions to swallow whole, storage temperature guidance, and a barcode. The label clearly marks it as prescription only (Rx Only).*

FDA Label Image

822-14 (822 14)

Desvenlafaxine 100 mg extended release tablets carton label from Marlex Pharmaceuticals, Inc. The label shows the proprietary and generic names, strength, and dosage form. It indicates 14 tablets per package and mentions dispensing instructions for pharmacists. The label also includes storage conditions, bar code, NDC, and lot and expiration date fields.*

FDA Label Image

822-30 (822 30)

Desvenlafaxine extended-release tablets 100 mg by Marlex Pharmaceuticals, Inc. The label shows dosage form as oral tablets with 30 count. It includes storage instructions, a barcode, and an NDC code 10135-0822-30. Directions state to swallow whole without crushing or chewing.*

FDA Label Image

822-90 (822 90)

Label for Desvenlafaxine extended-release tablets, 100 mg strength, from Marlex Pharmaceuticals, Inc. The label indicates the product contains 90 tablets and advises proper storage at 20° to 25°C with allowable excursions. It includes a barcode, lot number, and distributor information for Marlex Pharmaceuticals in New Castle, DE.*

FDA Label Image

Devstructure (Devstructure)

Chemical structure of desvenlafaxine, shown as a molecular diagram with labeled functional groups including hydroxyl, methylated amine, phenyl ring, and carboxyl groups, associated with water (hydrate).*

FDA Label Image

Fig4-study5relapsevs.randomization (Figure4)

A line graph depicting the estimated proportion of patients with relapse (%) on the Y-axis against time to relapse in days from randomization on the X-axis. Two lines compare Desvenlafaxine Extended-Release Tablets 50 mg and placebo, showing that patients on placebo have a higher relapse rate over time compared to those on Desvenlafaxine.*

FDA Label Image

Fig5-study6-relapsevs.randomization (Figure5)

A Kaplan-Meier curve showing the estimated proportion of patients with relapse (%) over time (days from randomization) comparing Desvenlafaxine extended-release tablets and placebo. The x-axis represents time to relapse up to approximately 180 days, and the y-axis shows the percentage of patients with relapse. Two lines represent treatment groups: a solid line for Desvenlafaxine and a dashed line for placebo.*

FDA Label Image

Figure2 (Fig2final2)

A chart illustrating the geometric mean ratio with 90% confidence intervals for the pharmacokinetic parameters Cmax and AUC of Desvenlafaxine when administered with the CYP3A4 inhibitor ketoconazole. The x-axis shows change relative to reference, ranging from 0.50 to 2.0, with Cmax near 1.08 and AUC near 1.43.*

FDA Label Image

Figure1 (Figure1)

A forest plot chart showing geometric mean ratios with 90% confidence intervals for pharmacokinetic parameters Cmax and AUC. The chart compares changes relative to reference values across categories including renal impairment (mild, moderate, severe, ESRD), hepatic impairment (mild, moderate, severe), and population groups by gender and age (>65 years and >75 years). The x-axis represents change relative to reference ranging from 0.5 to 3.5.*

FDA Label Image

Figure3 (Figure3)

A chart displaying geometric mean ratios with 90% confidence intervals for various interacting drugs at different doses of Desvenlafaxine (Pristiq). It shows changes in pharmacokinetic parameters such as Cmax and AUC relative to reference, with data separated by CYP2D6 and CYP3A4 substrates including Desipramine, Midazolam, Tamoxifen, and Aripiprazole.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.